Covid 19 Clinical Trials

	Name (Synonyms)	Correlation
drug1568	Naltrexone Wiki	0.58
drug375	Blood group determination Wiki	0.58
drug1297	Ketamine Wiki	0.58
drug2386	Surgical procedures performed under general anesthesia Wiki	0.58
drug193	Antibody titration Wiki	0.58
drug636	Control Wiki	0.22
drug1822	Placebo Wiki	0.03

Correlated MeSH Terms (9)

	Name (Synonyms)	Correlation
D001987	Bronchiectasis NIH	0.41
D014777	Virus Diseases NIH	0.07
D013577	Syndrome NIH	0.06
D045169	Severe Acute Respiratory Syndrome NIH	0.06
D055371	Acute Lung Injury NIH	0.06
D012127	Respiratory Distress Syndrome, Newborn NIH	0.06
D012128	Respiratory Distress Syndrome, Adult NIH	0.05
D018352	Coronavirus Infections NIH	0.05
D007239	Infection NIH	0.03

Correlated HPO Terms (1)

	Name (Synonyms)	Correlation
HP:0002110	Bronchiectasis HPO	0.41

There are 3 clinical trials

Clinical Trials

1 Multicentric Study to Assess the Effect of Consumption of Lactobacillus Coryniformis K8 on Healthcare Personnel Exposed to COVID-19

The aim of the present study is to evaluate the effects of Lactobacillus coryniformis K8 consumption on the incidence and severity of Covid-19 in health workers exposed to the virus. This is a preventive study

NCT04366180 Covid-19 Dietary Supplement: Probiotic Dietary Supplement: Control

Primary Outcomes

Description: The incidence of SARS CoV-2 infection will be confirmed by PCR or antigen test

Measure: Incidence of SARS CoV-2 infection in healthcare workers

Time: 8 weeks

Secondary Outcomes

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will required hospital admission because of Covid-19

Measure: Incidence of hospital admissions caused by SARS-CoV-2 infection

Time: 8 weeks

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will required ICU admission because of Covid-19

Measure: Incidence of ICU admissions caused by SARS-CoV-2 infection

Time: 8 weeks

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will develop pneumonia because of Covid-19

Measure: Incidence of pneumonia caused by SARS-CoV-2 infection

Time: 8 weeks

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will require oxygen support because of Covid-19

Measure: Incidence of oxygen support requirement caused by SARS-CoV-2 infection

Time: 8 weeks

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will develop gastrointestinal symptoms because of Covid-19

Measure: Incidence of gastrointestinal symptoms caused by SARS-CoV-2 infection

Time: 8 weeks

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with body's temperature > 37.5 ºC during the course of the disease

Measure: Days with body's temperature > 37.5 ºC

Time: 8 weeks

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with cough during the course of the disease

Measure: Days with cough

Time: 8 weeks

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with fatigue during the course of the disease

Measure: Days with fatigue

Time: 8 weeks

Description: Use of drugs (dosis and duration of the treatment) for Covid-19 treatment

Measure: Medical treatment

Time: 8 weeks

2 The Intestinal Microbiota as a Therapeutic Target in Hospitalized Patients With COVID-19 Infection

A prospective case-control pilot study to evaluate the possible effect of a probiotic mixture in the improvement of symptoms, the reduction in the number of days of hospitalization and the increase in the percentage of patients with negative PCR after infection with the coronavirus SARS-CoV-2.

NCT04390477 COVID-19 Coronavirus Infecti Coronavirus Infection Dietary Supplement: Probiotic

MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Percentage of patients with discharge to ICU.

Measure: Cases with discharge to ICU.

Time: 30-days

Secondary Outcomes

Description: Percentage of patients with home discharge.

Measure: Patients with home discharge.

Time: 30-days

Description: Percentage of deaths.

Measure: Mortality.

Time: 30-days

Description: Number of adverse events that occur during the treatment period, attributable or not to the intervention product.

Measure: Treatment safety assessed by number of adverse events.

Time: 30-days

Description: Number of new cases of positive SARS-Cov-2 infection by PCR analysis.

Measure: New cases of SARS-Cov-2 infection among healthcare personnel caring for the patients.

Time: 30-days

Description: Percentage of patients with negative PCR for SARS-CoV-2.

Measure: Patients with negative PCR result for SARS-CoV-2 infection.

Time: 30-days

3 Reduction of COVID 19 Transmission to Health Care Professionals

When the COVID-19 virus infects a person, it enters the lung epithelial cells of its host and uses its genetic material to replicate. The pulmonary epithelial cells of a part of the population, known as "secretors", are capable of expressing the antigens of the "ABO" system on their surface. This secretory status can be established by determining the antigens of the Lewis blood group system. When the virus replicates in an "secreting" individual, the antigens of the "ABO" system of the infected individual will be present on the surface of the viruses formed in his/her lungs. It was shown in 2003 that the response of a given individual to the transmission of a virus depends on his/her blood group and on the antigens of the "ABO" system carried by the virus. A patient of group "O" would thus defend himself much better against a virus carrying antigens of blood group "A", the natural antibodies "anti-A" of the patient reducing the ability of the virus to bind to its specific receptor on pulmonary epithelial cells, to penetrate them to replicate itself. The first data collected in Wuhan (China) seems to confirm this hypothesis. A COVID-19 virus transmission model can therefore be established on the basis of blood groups. In order to reduce the spread of the virus among nursing staff, it is possible to establish a preferential algorithm for patient management based on the "ABO" and "Lewis" blood groups of patients and "ABO" of nursing staff in health care units, if operational and human conditions allow.

NCT04462627 COVID 19 Diagnostic Test: Blood group determination Diagnostic Test: Antibody titration Dietary Supplement: Probiotic

Primary Outcomes

Description: Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

Measure: Anti-A antibody concentration

Time: baseline

Description: Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

Measure: Anti-A antibody concentration

Time: Day 4

Description: Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

Measure: Anti-A antibody concentration

Time: Week 1

Description: Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

Measure: Anti-A antibody concentration

Time: Week 2

Description: Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

Measure: Anti-A antibody concentration

Time: Week 3

Description: Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.